Stockscreener 앱 받기
16.75
10.24%
-1.91
시간 외 거래:
16.76
0.01
+0.06%
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 6%Here's Why - MarketBeat
Assessing Monte Rosa Therapeutics After Its 162.4% Surge and DCF Implied Upside in 2025 - Yahoo Finance
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Rating of "Hold" by Brokerages - MarketBeat
Monte Rosa Therapeutics announces data from Phase 1/2 study of MRT-2359 - Yahoo Finance
Wells Fargo Upgrades Monte Rosa Therapeutics (GLUE) - Nasdaq
GSPT1 chat favorable as Monte Rosa scores in prostate phase I/II - BioWorld MedTech
Why Is Monte Rosa Stock Trading Higher Today? - Benzinga
Monte Rosa reports promising results for MRT-2359 in prostate cancer - Investing.com Nigeria
Wedbush Adjusts Monte Rosa Therapeutics Price Target to $26 From $19, Maintains Outperform Rating - marketscreener.com
Monte Rosa Therapeutics (NASDAQ:GLUE) Sets New 52-Week HighShould You Buy? - MarketBeat
Monte Rosa Therapeutics (GLUE) Receives Analyst Upgrade and Pric - GuruFocus
Monte Rosa Therapeutics Says Advanced Prostate Cancer Combination Therapy Trial Shows 64% Disease Control - marketscreener.com
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Adjusts Price Target to $22 From $13 - marketscreener.com
Monte Rosa Reports Positive Phase 1/2 Study Results - TipRanks
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations - Investing News Network
Monte Rosa Therapeutics : Corporate Presentation – December 2025 - marketscreener.com
Monte Rosa Therapeutics Announces Positive Interim Data for MRT-2359 in Prostate Cancer - TradingView — Track All Markets
Monte Rosa Therapeutics announces compelling clinical activity of MRT-2359 in combination with enzalutamide - marketscreener.com
Monte Rosa Therapeutics, Inc. Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations - marketscreener.com
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results - The Manila Times
Monte Rosa Therapeutics to Host Conference Call on Interim Results of MRT-2359 for mCRPC Treatment - Quiver Quantitative
Monte Rosa (Nasdaq: GLUE) to share MRT-2359 mCRPC Phase 1/2 data Dec. 16 - Stock Titan
Franklin Resources Inc. Raises Stock Holdings in Monte Rosa Therapeutics, Inc. $GLUE - Defense World
Monte Rosa Therapeutics (NASDAQ:GLUE) Nasdaq Futures Biotech Momentum - Kalkine Media
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates - sharewise.com
Critical Survey: Monte Rosa Therapeutics (NASDAQ:GLUE) & Cogent Biosciences (NASDAQ:COGT) - Defense World
Monte Rosa Therapeutics stock hits 52-week high at $16.66 By Investing.com - Investing.com India
Monte Rosa Therapeutics stock hits 52-week high at $16.66 - Investing.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st
Monte Rosa Therapeutics (GLUE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Improved Revenues Required Before Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock's 26% Jump Looks Justified - 富途牛牛
Monte Rosa: Looking Mispriced After Big Pharma Validation (NASDAQ:GLUE) - Seeking Alpha
How Monte Rosa Therapeutics Inc. stock reacts to inflationary pressuresQuarterly Earnings Summary & Real-Time Buy Signal Notifications - moha.gov.vn
Monte Rosa Therapeutics Jumps 124.9% in 2025 But Are Investors Getting Ahead of Themselves - Yahoo Finance
Hillsdale Investment Management Inc. Makes New $271,000 Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Hits New 12-Month HighShould You Buy? - MarketBeat
Monte Rosa Therapeutics, Inc. (GLUE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Head-To-Head Review: Twist Bioscience (NASDAQ:TWST) versus Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics Inc. (GLUE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Price momentum metrics for Monte Rosa Therapeutics Inc. explainedChart Signals & Proven Capital Preservation Tips - newser.com
Los Angeles Capital Management LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics finds novel molecular glue degrader - Traders Union
What to do if you’re stuck in Monte Rosa Therapeutics Inc.July 2025 Snapshot & AI Forecasted Entry/Exit Points - newser.com
Integrated Quantitative Investments LLC Acquires New Holdings in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics Reports Strong Revenue Growth - MSN
22,500 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Bailard Inc. - MarketBeat
What analysts say about Monte Rosa Therapeutics Inc stockFibonacci Retracement Levels & Free Explosive Earning Power - earlytimes.in
Is Monte Rosa Therapeutics Inc. meeting your algorithmic filter criteriaEarnings Miss & Verified Trade Idea Suggestions - newser.com
Is it time to cut losses on Monte Rosa Therapeutics Inc.Quarterly Investment Review & Entry and Exit Point Strategies - newser.com
Why Monte Rosa Therapeutics Inc. stock could benefit from AI revolutionMarket Volume Summary & Technical Pattern Alert System - newser.com
Custom watchlist performance reports with Monte Rosa Therapeutics Inc.Quarterly Growth Report & Community Driven Trade Alerts - newser.com
Why Monte Rosa Therapeutics Inc. stock is popular among millennialsJuly 2025 Highlights & Fast Moving Market Watchlists - newser.com
Published on: 2025-11-14 03:37:36 - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Applied Therapeutics (APLT) and Xilio Therapeutics (XLO) - The Globe and Mail
0.18%
0.62%
자본화:
|
볼륨(24시간):